Liraglutide

Liraglutide is an acylated analog of human glucagon-like peptide-1 (GLP-1) that shares roughly 97% sequence homology with the native hormone. A single amino-acid substitution and the attachment of a C16 palmitic fatty-acid chain via a glutamyl spacer promote reversible binding to serum albumin, which slows renal clearance and protects the molecule from degradation by dipeptidyl peptidase-4 (DPP-4), extending its half-life to about 13 hours and supporting once-daily dosing. As a selective GLP-1 receptor agonist it stimulates glucose-dependent insulin secretion, suppresses inappropriately elevated glucagon, slows gastric emptying, and acts on hypothalamic and brainstem appetite centers to enhance satiety and reduce food intake.

Liraglutide is supported by one of the more mature clinical programs among GLP-1 agonists. The LEADER cardiovascular outcomes trial (Marso et al., NEJM 2016) enrolled 9,340 patients with type 2 diabetes at high cardiovascular risk and reported a significant reduction in major adverse cardiovascular events (13.0% vs 14.9% with placebo over a median 3.8 years). For weight management, the SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., NEJM 2015) reported a mean 8.4 kg (8.0%) weight loss at 56 weeks with 3.0 mg daily versus 2.8 kg with placebo. This evidence underlies FDA and EMA approval for glycemic control (Victoza) and chronic weight management (Saxenda). Grey-market 'research' liraglutide is not the approved medicine and carries none of these assurances.

Educational overview only — no dosing instructions in the public hub.

The most common adverse effects are gastrointestinal — nausea, vomiting, diarrhea, and constipation — generally dose-dependent and most pronounced during dose escalation. Documented serious risks include acute pancreatitis, gallbladder disease (cholelithiasis/cholecystitis), acute kidney injury (often secondary to GI-related fluid loss), and hypoglycemia when combined with insulin or sulfonylureas. It carries a boxed warning for thyroid C-cell tumors based on rodent studies (human relevance unconfirmed; contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2). It is a prescription medicine to be used only under medical supervision. Non-prescription, 'research use only,' or compounded liraglutide products carry additional unquantified risks: uncertain dosing accuracy, impurities, and no clinical oversight to manage side effects or contraindications.

Liraglutide is a genuine prescription biologic with a narrow margin between effective dosing and gastrointestinal intolerance, making source and formulation integrity critical. Only a pharmacy-dispensed, approved product offers verified identity and purity; grey-market vials sold as 'research grade' are of unverified composition and outside any regulatory oversight. Content here reflects the approved pharmaceutical product as studied in registered trials, not gray-market material.

Approved prescription-only medication (FDA and EMA), marketed as Victoza (type 2 diabetes, approved 2010) and Saxenda (chronic weight management, approved 2014), requiring a physician's prescription and medical supervision. It is not a research chemical. Non-prescription or compounded liraglutide sold outside this regulatory framework is not approved for human use and lacks quality assurance.